COMP <GO>
KYMR vs LLY // FREE CASH FLOW YIELD
Kymera Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: KYMR 4
— LLY 10
▲ FREE CASH FLOW YIELD LEADER: LLY
LAST: $126.63 (+3.29%) • MKT CAP: $10.19B
fcf-yield
-2.30%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
fcf-yield
2.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYMR VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KYMR | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 0.00% | 83.64% | -83.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.40% | 32.36% | -53.76 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -2.30% | 2.30% | -4.60 | LLY | /fcf-yield <GO> |
| Operating Margin | -60.00% | 40.21% | -100.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 31.90% | +36.10 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | -16.70% | 45.51% | -62.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.29 | +16.71 | KYMR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.77% | -0.07 | KYMR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.3 | 77.9 | -8.55 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.51 | +0.44 | KYMR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.4x | 26.3x | +4.15 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.19B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KYMR REV | LLY REV | KYMR GROSS % | LLY GROSS % | KYMR FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $39.2M | $65.18B | 0.0% | 83.0% | -$234.3M | $16.81B |
| FY 2024 | $47.1M | $45.04B | 0.0% | 81.3% | -$207.3M | $8.82B |
| FY 2023 | $78.6M | $34.12B | 44.0% | 79.3% | -$106.4M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYMR // BETA 0.95
LLY // BETA 0.51